Clinical effect of Danshen decoction in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials

作者：Ziyi Li, Mengnan Liu, Mingtai Chen, Gang Luo, Jiao Wu, Maryam Mazhar, Fang Yang, Yu Zheng, Hao Wu, Qibiao Wu, Sijin Yang · 发表于：PLoS ONE · 年份：2023 · DOI：10.1371/journal.pone.0284877 · 被引用次数：18 · 研究领域：Traditional Chinese Medicine Analysis、Traditional Chinese Medicine Studies、Plant-based Medicinal Research

BACKGROUND: The incidence of heart failure (HF) is increasing year by year, posing a great threat to human health. Although pharmacotherapy has been able to significantly prolong patient survival, pharmacotherapy for HF still has limitations due to its complex pathogenesis and considerable individual variability, there is a great need to explore complementary and alternative therapies to slow down the progression of HF. Danshen decoction is used to treat several cardiovascular diseases including HF, but the efficacy of stabilization is uncertain. This meta-analysis evaluated the clinical efficacy of Danshen Decoction for the treatment of HF. METHODS: The registration number assigned to this meta-analysis on the PROSPERO platform is CRD42022351918. Four databases were searched, and randomized controlled trials (RCTs) of Danshen decoction combined with conventional treatment (CT) of HF were screened, CT included medical treatments other than Danshen Decoction to which the patient was treated (including but not limited to angiotensin converting enzyme inhibitor, angiotensin receptor blocker, angiotensin receptor neprilysin inhibitors, β-blockers, diuretics, mineralcorticoid recept antagonist etc.). The clinical efficacy rate (CER), left ventricular ejection fraction (LVEF), left ventricular end-diastolic dimension (LVEDD), left ventricular end-systolic diameter (LVESD), brain natriuretic peptide (BNP), N-terminal pro-B type natriuretic peptide (NT-proBNP) and hypersensitive C-re...